Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2015

Open Access 01-03-2015 | Review Article - Safety Review

Treatment of rheumatic diseases and hepatitis B virus coinfection

Authors: Anna Felis-Giemza, Marzena Olesińska, Katarzyna Świerkocka, Ewa Więsik-Szewczyk, Ewa Haładyj

Published in: Rheumatology International | Issue 3/2015

Login to get access

Abstract

We often encounter rheumatological patients coinfected with hepatitis B in daily practice. In this paper, we will discuss the basic characteristics of the virus of hepatitis B, course of infection, the safety of rituximab, tocilizumab, abatacept treatment and therapeutic recommendations in management of patients with rheumatic diseases.
Literature
1.
2.
3.
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF (2001) Nomenclature for antiviral resistant of human hepatitis B virus mutations in the polymerase region. Hepatology 33:751–757CrossRefPubMed
4.
Ferir G, Kaptein S, Neyts J, De Clercq E (2008) Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 18:19–34CrossRefPubMed
5.
Morgan M, Keeffe EB (2009) Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva Gastroenterol Dietol 55:5–22PubMed
6.
Pungpapong S, Kim WR, Poterucha JJ (2007) Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 82:967–975CrossRefPubMed
7.
Winthrop KL, Calabrese LH (2011) Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70:1701–1703CrossRefPubMed
8.
Szczeklik A (2010) Choroby wewnętrzne. Medycyna Prakt, pp 967–980
9.
Chisari FV, Isogawa M, Wieland S (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58(4):258–266CrossRef
10.
Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Büning H, Rose-John S, Protzer U (2009) Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50(6):1773–1782CrossRefPubMed
11.
Puro R, Schneider RJ (2007) Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 81(14):7351–7362CrossRefPubMedCentralPubMed
12.
Yapali S, Talaat N, Lok AS (2014) Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 12(1):16–26CrossRefPubMed
13.
de Franchis R, Hadengue A, Lau G et al (2003) EASL Jury. EASL International consensus conference on hepatitis B. Consensus statement (long version). J Hepatol 39(Suppl. 1):S3–S25PubMed
14.
Tang JR, Hsu HY, Lin HH et al (1998) Hepatitis B surface antigenemia at birth: a long-term followup study. J Pediatr 133:374–377. www.​who.​int
15.
Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NWY, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307CrossRefPubMed
16.
Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209–220CrossRefPubMed
17.
Brojer E (2009) Ukryte zakażenie wirusem HBV w hematologii i transfuzjologii. Acta Haematol Pol 40(2):435–449
18.
Vassilopoulos D (2011) Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Int Med 22:572–575CrossRef
19.
Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009–1022CrossRefPubMed
20.
Evens AM, Jovanovic BD, Su YC et al (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180CrossRefPubMedCentralPubMed
21.
Mendez-Navarro J, Corey KE, Zheng H et al (2011) Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int 31:330–339CrossRefPubMedCentralPubMed
22.
Chen XQ, Peng JW, Lin GN et al (2012) The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg—positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 29:1237–1241CrossRefPubMed
23.
Pyrpasopoulou A, Douma S, Vassiliadis T et al (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31:403–404CrossRefPubMed
24.
Mitroulis I, Hatzara C, Kandili A et al (2013) Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 72:308–310CrossRefPubMed
25.
Tsutsumi Y, Shigematsu A, Hashino S et al (2009) Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol 88(4):375–377CrossRefPubMed
26.
Yang SH, Kuo SH (2008) Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 87(4):325–327CrossRefPubMed
27.
Yeo W, Chan TC, Leung NWY et al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27(4):605–611CrossRefPubMed
28.
Nagashima T, Minota S (2008) Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47:1838–1840CrossRef
29.
Nagashima T, Maruyama A, Kamata Y et al (2011) Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 32:2231–2232CrossRefPubMed
30.
Tsuboi H, Tsujii A, Nampei A et al (2011) A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol 21:701–705CrossRefPubMed
31.
Kim PS, Ho GY, Prete PE et al (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 64:1265–1268
32.
Ghrenassia E, Meknian A, Rouaghe S, Granne N, Fain O (2012) Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 79:100–101CrossRefPubMed
33.
Salman-Monte TC, Lisbona MP, García-Retortillo M, Maymóa J (2014) Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin 10(3):191–200CrossRef
34.
Germanidis G, Hytiroglou P, Zakalka M, Settas L (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56(6):1420–1421CrossRefPubMed
35.
Vassilopoulos D, Calabrese LH (2012) Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 8(6):348–357CrossRefPubMed
36.
37.
Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963CrossRefPubMed
38.
Xuan D, Yiqi Y, Shao L, Wang J, Zhang W, Zou H (2014) Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy—a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 33:577–586CrossRefPubMedCentralPubMed
39.
Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS (2012) A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 18(2):225–228CrossRefPubMedCentralPubMed
40.
41.
Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y (2012) Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 22(3):470–473CrossRefPubMed
42.
Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21(1):16–23CrossRefPubMed
43.
Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31(8):1169–1175CrossRefPubMed
44.
Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46(4):556–564CrossRefPubMed
45.
Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F (2001) Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 44(2):339–342CrossRefPubMed
46.
Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S (2014) Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease modifying antirheumatic drugs. Int J Rheum Dis. doi:10.​1111/​1756-185X.​12359
47.
Lee YM, Kang M, Hwang JM, Lee S, Cho H, Kim YS (2010) Sulfasalazine induces apoptosis of HBxexpressing cells in an NF-kappaB-independent manner. Virus Genes 40(1):37–43CrossRefPubMed
48.
Thong BY, Koh ET, Chng HH, Chow WC (2007) Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases. Ann Acad Med Singap 36(2):100–105PubMed
49.
Narváez J, Rodriguez-Moreno J, Martinez-Aguilá MD, Clavaguera MT (1998) Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 25(10):2037–2038PubMed
50.
Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N (2004) Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of lowdose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 22(3):375–376PubMed
51.
Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS (2000) Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18(3):363–368PubMed
52.
Helbling B, Reichen J (1994) Reactivation of hepatitis B following withdrawal of chloroquine. Schweiz Med Wochenschr 124(18):759–762PubMed
53.
Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N (2013) Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 41:225–229CrossRefPubMed
54.
Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F (2008) Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 83:673–675CrossRefPubMed
55.
Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N (2014) Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 6(6):384–393CrossRefPubMedCentralPubMed
56.
Viganò M, Mangia G, Lampertico P (2014) Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 14(7):1019–1031CrossRefPubMed
57.
58.
Weaver AL (2003) Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 9:99–114CrossRefPubMed
59.
Peterson JR, Hsu FC, Simkin PA et al (2003) Effect of tumor necrosis factor α antagonism on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082CrossRefPubMedCentralPubMed
60.
Su F, Schneider RJ (1997) Hepatitis B virus Hbx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc Natl Acad Sci USA 94:8744–8749CrossRefPubMedCentralPubMed
61.
Maini MK, Boni C, Lee CK (2000) The role of virus specific CD8 + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269–1280CrossRefPubMedCentralPubMed
62.
Millonig G, Kern M, Ludwiczek O et al (2006) Subfulminant hepatitis B after infliximab in Crohn’ disease: need for HBV-screening? World J Gastroenterol 12:974–976PubMedCentralPubMed
63.
Uhl EW, Moldawer LL, Busse WW et al (1998) Increased tumor necrosis factor α (TNF-α) gene expression in parainfluenza type 1 (Sendai) virus-inducted bronchiolar fibrosis. Am J Pathol 152:513–522PubMedCentralPubMed
64.
Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh ChW, Chen DY, Yang SS (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70:1719–1725CrossRefPubMed
65.
Loomba R, Rowley A, Wesley R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528CrossRefPubMedCentralPubMed
66.
Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F et al (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90(6):359–371CrossRef
67.
Giles JT, Bathon JM (2004) Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19:320–334CrossRefPubMed
68.
Keane J, Gershon S, Wise SP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098–1103CrossRefPubMed
69.
Carrol BM, Bond IM (2008) Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38:208–217CrossRef
70.
Thimme R, Wieland S, Steiger C et al (2003) CD8 + cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68–76CrossRefPubMedCentralPubMed
71.
Sakellaoriu GT, Chatzigiannis I (2007) Long term anti-TNF-alpha therapy for ankylosis spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26:950–952CrossRef
72.
Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor hepatitis α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563CrossRefPubMed
73.
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev8:104–106CrossRefPubMed
74.
Furst DE, Keystone EC, Braun J et al (2011) Updated consensus statement on biological agents for the treatment of rheumatic diseases 2010. Ann Rheum Dis 70(Suppl 1):i2–i36CrossRefPubMed
75.
Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371CrossRefPubMed
76.
Wendling D, Di Martino V, Prati C et al (2009) Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 76:308–311CrossRefPubMed
77.
Marzano A, Angelucci E, Andreone P et al (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397–408CrossRefPubMed
78.
Galeazzi M, Bellisai F, Giannitti C et al (2007) Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann NY Acad Sci 1110:544–549CrossRefPubMed
79.
Giannitti C, Benucci M, Caporali R et al (2009) Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 22:543–546PubMed
80.
Esteve i Comas M, Saro C, Gonzales-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365CrossRef
81.
Michel M, Duvoux C, Hezode C et al (2003) Fulminant hepatitis after infliximab in patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 30:1624–1625PubMed
82.
Caporali R, Bobbio-Pallavicini F, Atzeni F et al (2010) Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 62:749–754CrossRef
83.
Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687CrossRefPubMedCentralPubMed
84.
Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36:2416–2420CrossRefPubMed
85.
Kim YJ, Bae SC, Sung YK et al (2010) Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 37:346–350CrossRefPubMed
86.
Singh JA, Furst DE, Bharat A et al (2012) 2012 Update of the 2008 American College of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625–639CrossRef
87.
Zingarelli S, Frassi M, Bazzani C et al (2009) Use of tumor necrosis factor-α-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 36:1189–1194
Metadata
Title
Treatment of rheumatic diseases and hepatitis B virus coinfection
Authors
Anna Felis-Giemza
Marzena Olesińska
Katarzyna Świerkocka
Ewa Więsik-Szewczyk
Ewa Haładyj
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3195-8

Other articles of this Issue 3/2015

Rheumatology International 3/2015 Go to the issue

Short Communication - Safety and Pharmacovigillance

Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study

Original Article - Observational Research

Positive and negative affective states and disease activity in ankylosing spondylitis

Erratum

Erratum to: Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region

Original Article - Guidelines

Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis

Review Article - Clinical Trials

Physical activity in spondyloarthritis: a systematic review

Letter to the Editor - Food for Thought

Letter to: “Vitamin D levels and bone mass in rheumatoid arthritis”
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits